Muscle and joint pain can interfere with exercise, employment, sleep and everyday independence. Although treatment depends on the underlying cause, topical preparations offer a convenient way to manage local discomfort. Fisiocrem is a brand of externally applied products promoted for musculoskeletal symptoms. Its best-known formulation, fisiocrem Solugel, combines botanical extracts with menthol. It may provide useful short-term relief for some people, but its benefits should be considered alongside the limitations of the evidence. Importantly, reducing pain does not necessarily mean that an injured muscle, tendon or joint has healed.

Ingredients and proposed actions

The Solugel formulation contains extracts of Arnica montana, Calendula officinalis and Hypericum perforatum, together with Melaleuca alternifolia oil and menthol. Arnica has traditionally been used for bruising and muscular discomfort. Calendula, commonly called pot marigold, has a history of use in skin preparations, while hypericum is better known as St John’s wort. Melaleuca, or tea tree oil, has antimicrobial properties. However, traditional use and laboratory findings do not automatically establish clinically important pain relief when these substances are combined and applied over deeper musculoskeletal tissues.

Menthol provides a clearer explanation for the immediate cooling sensation. It activates cold-sensitive receptors, particularly TRPM8, and can modify the perception of pain. This sensory effect may make an uncomfortable area feel more comfortable without changing its structural condition. Gentle rubbing during application may also provide temporary relief through touch, relaxation and altered sensory input. Consequently, the overall experience can reflect the formulation, the massage and the person’s expectations. It is difficult to determine how much each botanical ingredient contributes without trials comparing the components separately.

Evidence of effectiveness

A product-specific randomised, double-blind, placebo-controlled trial published in 2022 enrolled 200 adults with acute or chronic musculoskeletal pain. Participants were allocated to fisiocrem or a similar cream without active ingredients, applied twice daily for fourteen days. The researchers reported greater reductions in pain and perceived stiffness with fisiocrem, with differences detectable thirty minutes after application. Participants receiving the active preparation also reported better recovery perceptions during follow-up. These findings support the possibility of symptomatic benefit beyond that provided by applying and massaging a placebo cream.

Nevertheless, this study does not settle every question about effectiveness. It was funded by fisiocrem, lasted only two weeks and included several different diagnoses, including tendinopathy, sprains, spinal pain and symptomatic osteoarthritis. Such diversity makes condition-specific conclusions difficult. Menthol’s distinctive sensation may also complicate blinding, even when preparations look similar. Furthermore, measured joint mobility did not differ significantly between groups. Independent replication, longer follow-up and comparisons with established treatments would strengthen confidence. Improvements in reported pain or recovery should not be interpreted as proof of accelerated tissue repair or lasting disease modification.

Evidence concerning individual ingredients must also be interpreted cautiously. A Cochrane review found that one trial of a particular arnica gel suggested similar symptom benefits to topical ibuprofen in hand osteoarthritis. However, this cannot establish that fisiocrem works equally well, because extraction methods, concentrations and accompanying ingredients differ. More broadly, topical nonsteroidal anti-inflammatory drugs, such as diclofenac, have a larger evidence base for certain musculoskeletal conditions. Fisiocrem therefore represents an optional symptomatic treatment rather than an evidence-equivalent replacement for every established therapy.

Practical clinical use

For muscle pain, fisiocrem may be considered for localised aches after unfamiliar exercise, mild muscular strains or tension-related discomfort. Its non-greasy formulation and easy application may encourage use, particularly among people who prefer topical treatments. Nevertheless, exercise-related soreness usually improves naturally, making personal impressions of effectiveness difficult to separate from normal recovery. Persistent or recurrent symptoms require attention to training load, strength, movement habits and recovery. Pain relief should support appropriate activity, not encourage someone to continue exercising through an injury that is becoming progressively worse.

For joint pain, expectations should be similarly realistic. A topical preparation may ease discomfort around a painful joint, but it cannot rebuild damaged cartilage, correct instability or control systemic inflammatory arthritis. Exercise therapy, education and condition-specific management remain important. The brand also markets a separate Joint Ease formulation containing additional ingredients, including boswellia and black seed oil. Products bearing the same brand name are not interchangeable: evidence concerning Solugel should not automatically be applied to other formulations. Users should check exactly which product they have and its intended indications.

A practical approach is to judge benefit by function as well as pain scores. For example, does application make walking, prescribed exercises or ordinary household tasks more comfortable? If there is no worthwhile improvement, continued use adds cost without clear value. Even when helpful, the cream should accompany gradual strengthening and appropriate load modification. People taking other medicines or managing several health conditions can ask a pharmacist whether a topical herbal preparation is a sensible individual choice.

Application and safety

The Australian Solugel directions advise applying a few grams to the affected area three to four times daily as required. Users should follow their own pack’s instructions, since formulations and recommendations may vary between countries. Apply only to intact skin, avoid the eyes and mucous membranes, and wash the hands afterwards unless treating them. Gentle application is preferable to forceful massage over a recently injured area. Avoid combining topical pain products on the same site or using heating pads or tight coverings unless a healthcare professional confirms this is appropriate.

“Natural” does not mean free from adverse effects. Arnica, calendula, tea tree oil and other constituents can cause irritation or allergic contact dermatitis. People with allergies to plants in the daisy family should be particularly cautious about arnica and calendula. Stop using the product if redness, itching, blistering or worsening discomfort develops. Seek advice before use during pregnancy, breastfeeding or in children. People with fragile skin, impaired sensation or diabetes-related neuropathy should also obtain guidance. Fisiocrem must never be swallowed or applied to open wounds.

Overall, fisiocrem may offer temporary relief of muscle and joint discomfort, with some supportive clinical evidence but important uncertainties. It is best used as an adjunct to diagnosis, rehabilitation and sensible activity management, rather than as a cure. Severe pain, inability to bear weight, fever or a hot, swollen joint warrants prompt assessment.

Formthotics are prefabricated, heat-mouldable foot orthoses designed to fit inside footwear and modify the interaction between the foot, shoe and ground. Used by podiatrists and other health professionals, they offer an adaptable alternative to both simple cushioning insoles and individually manufactured orthoses. Their value lies principally in improving comfort, redistributing pressure and altering loads on painful tissues. However, they should not be regarded as a universal correction for abnormal foot posture. Successful treatment depends on accurate diagnosis, fitting and integration with other measures, including exercise and suitable footwear.

The devices are manufactured from a proprietary closed-cell polyethylene foam called Formax. Different models offer varying densities, thicknesses and combinations of cushioning and support. Unlike a rigid plastic orthosis, the foam is flexible and can be heated and moulded to accommodate the foot within the shoe. Clinicians can further adapt the device using wedges, pads or local modifications. Although this process individualises the fit, it does not make Formthotics equivalent to an orthosis manufactured from an individual cast or scan. They remain prefabricated devices that are adjusted to meet needs.

Their effects are best understood through load management rather than the simplistic idea of placing every foot into an ideal alignment. Increasing contact beneath the arch can redistribute plantar pressure, while cushioning may reduce discomfort at sensitive areas. Changes in the forces acting beneath the foot can also influence the demands placed on muscles, tendons and joints. The response varies between individuals and depends on footwear and activity. Pronation is a normal component of walking and running; its presence alone does not establish a problem or justify prescribing an orthosis.

One indication is plantar heel pain, often called plantar fasciitis. Formthotics may help some patients tolerate standing and walking by changing plantar loading and supporting the arch. Nevertheless, relief is neither immediate nor guaranteed. A randomised trial by Landorf and colleagues found that prefabricated and customised orthoses produced small short-term functional benefits compared with sham devices, without advantages at twelve months. The 2023 plantar fasciitis guideline recommends against using orthoses as an isolated treatment. They are more appropriately combined with plantar fascia and calf stretching, strengthening, education and activity adjustment.

Formthotics may also be considered for painful flexible flat feet when symptoms are associated with prolonged standing, walking or sporting activity. The aim is to improve comfort and functional tolerance, not permanently reconstruct the arch. In adults with progressive arch collapse or posterior tibial tendon dysfunction, a simple insert may provide insufficient support, and bracing or specialist management may be required. Similarly, painless flexible flat feet in children usually do not require treatment merely because their arches appear low. Prescribing should be driven by symptoms and clinical findings rather than appearance alone.

Forefoot pain provides another potential application. In selected cases of metatarsalgia, modifications such as a correctly positioned metatarsal pad can redistribute loading away from painful metatarsal heads. Footwear must provide sufficient width and depth, because an insert placed in a tight shoe can increase compression and worsen symptoms. Conditions such as interdigital nerve irritation, joint inflammation and stress injury require different management despite producing similar pain. Formthotics may complement treatment, but persistent focal pain should prompt reassessment rather than repeated insole adjustments without a clear diagnosis of the underlying cause.

For runners and other active people, these orthoses can sometimes reduce symptoms sufficiently to support rehabilitation. However, evidence for foot orthoses in general should not automatically be interpreted as proof that this particular brand prevents injuries or outperforms alternatives. Neither comfort during an initial fitting nor a visible change in foot posture establishes lasting clinical benefit. Training errors, inadequate recovery, muscle capacity and footwear remain important considerations. An orthosis should support a progressive return to activity, rather than allow an athlete to continue overloading an injured structure without appropriate rehabilitation.

Clinical assessment should consider pain location, symptom behaviour, skin condition, joint mobility, strength, gait and the shoes in which the orthoses will be worn. Selection of foam density and device shape should reflect the treatment objective, available shoe space and patient preference. Heat moulding and additional modifications should follow the manufacturer’s instructions. A gradual introduction is often sensible, with wear time increased according to comfort. Review should assess meaningful outcomes such as walking tolerance and pain during daily activities, rather than assuming that a more visibly supported arch represents success.

Safety is particularly important in people with diabetes, peripheral neuropathy, poor circulation or previous ulceration. These patients may not detect excessive pressure or rubbing, so professional assessment and careful skin monitoring are essential. Standard Formthotics are not automatically suitable for treating an active ulcer or replacing specialised offloading devices. New blisters, persistent redness, numbness or increasing pain warrant stopping use and obtaining advice. The devices also need periodic inspection: compressed foam, wear and changes in footwear or symptoms may require modification or replacement. Their useful lifespan varies with loading and use.

Overall, Formthotics offer a practical, accessible means of individualising prefabricated foot orthoses. Their adjustability and cushioning make them useful for selected painful foot conditions, particularly when a comfortable device can facilitate movement and rehabilitation. Their limitations are equally important: they do not correct every biomechanical variation, guarantee injury prevention or replace a diagnosis. The strongest clinical approach is therefore selective and outcome-focused, combining an appropriately fitted orthosis with education, footwear advice, exercise and review. Used this way, Formthotics are a valuable component of care rather than a standalone cure.

Heel pain can interfere with walking, employment, exercise and everyday independence. One common cause is plantar fasciitis, a condition affecting the strong connective tissue beneath the foot. Although treatments often focus on cushioning, stretching or reducing activity, rehabilitation increasingly includes progressive strengthening. The Fasciitis Fighter is a commercially available exercise aid designed to facilitate this approach. Its potential value lies in making a particular heel-raise exercise convenient and repeatable, rather than providing a passive cure. Understanding its role requires distinguishing the evidence supporting progressive exercise from evidence demonstrating the effectiveness of the branded device itself.

Understanding plantar heel pain

The plantar fascia extends from the heel towards the toes and helps support the longitudinal arch. During standing, walking and running, it contributes to managing forces and stiffening the foot for propulsion. Plantar fasciitis typically causes pain near the inner underside of the heel, especially during the first steps after sleep or prolonged sitting. Symptoms may initially ease with movement before returning during sustained activity. Although the name suggests inflammation, persistent cases commonly involve changes in collagen organisation and tissue structure. Consequently, plantar fasciopathy is often a more useful term, recognising that longstanding symptoms are not simply an inflammatory problem.

However, heel pain is not a single diagnosis. Calcaneal stress fractures, heel fat-pad disorders, nerve entrapment and inflammatory disease may produce similar complaints. Pain behind the heel may instead involve the Achilles tendon. A strengthening device intended for plantar fasciopathy should therefore follow an appropriate assessment, particularly when symptoms are atypical or severe.

How the Fasciitis Fighter works

The Fasciitis Fighter provides a shaped surface beneath the toes during heel raises. Its raised contour holds the toes, particularly the big toe, in extension while the forefoot remains supported. As the person lifts the heel, the calf muscles work against body weight. Toe extension also tensions the plantar fascia through the windlass mechanism: the fascia winds around the metatarsal heads, helping raise and stiffen the arch. Combining these actions provides a practical way of loading the calf–foot system while increasing tension through the plantar fascia.

This is different from rolling the heel over a massage ball or resting on a cushioned insert. The aim is to improve physical capacity through repeated, progressively challenging exercise. Mechanical loading may encourage connective-tissue adaptation and improve muscular strength, although the precise relationship between these changes and pain relief remains uncertain. Claims that the device directly repairs damaged fascia or permanently corrects foot mechanics therefore exceed what can confidently be concluded.

What does the evidence show?

A frequently cited randomised trial by Rathleff and colleagues compared plantar fascia-specific stretching with high-load strengthening in 48 people with ultrasound-confirmed plantar fasciitis. Both groups also received shoe inserts. Strengthening involved single-leg heel raises performed every second day, with a rolled towel beneath the toes. At three months, the strengthening group had a Foot Function Index score 29 points lower than the stretching group, indicating less pain-related disability. However, statistically significant differences were not found at one, six or twelve months. The findings suggest that progressive strengthening may accelerate improvement, not that it guarantees superior long-term outcomes.[1]

Crucially, this trial investigated an exercise programme, not the Fasciitis Fighter. It cannot establish that purchasing the device produces better outcomes than using a towel or another suitable support. The manufacturer’s instructions help explain positioning, but commercial descriptions and testimonials are not substitutes for independent comparative trials. Contemporary clinical guidelines recommend resistance training for the foot and ankle musculature, supporting the general rehabilitation principle rather than endorsing this particular product.

Using the device appropriately

Exercise should begin at a level the individual can tolerate. Someone unable to perform controlled single-leg heel raises may start with both legs, partial weight-bearing assistance or a simpler variation. A stable hand support can improve balance. The ball of the big toe should remain supported while the toe rests over the raised contour; forcing a painful or stiff toe into excessive extension is inappropriate.

The research-based exercise commonly uses a slow rhythm: approximately three seconds rising, a two-second pause and three seconds lowering. Sessions are generally separated by a recovery day. Resistance can increase gradually as capacity improves, for example by progressing from bilateral to unilateral raises or adding weight in a securely fitted backpack. Exact repetitions, sets and progression should reflect strength, symptoms and clinical advice rather than a rigid universal prescription.

Some discomfort may be acceptable, but sharp pain, deteriorating technique or substantial worsening afterwards suggests excessive loading. First-step pain the following morning is a useful monitoring measure. A sustained increase should prompt reduced resistance, fewer repetitions or reassessment. Meaningful improvement usually requires consistent work over weeks to months, not a few sessions.

Benefits, limitations and wider management

The device’s main advantages are convenience, portability and a consistent toe-support shape. These features may help people perform exercises regularly, especially when a rolled towel feels awkward. Nevertheless, it adds cost, and not everyone tolerates its contour. People with painful big-toe arthritis, impaired balance, neuropathy, poor circulation or skin damage may require modifications or professional supervision. Sudden severe pain, marked swelling, inability to bear weight or unexplained rest pain requires assessment rather than heavier exercise.

Strengthening should sit within broader management. Temporarily reducing provocative running or prolonged standing, choosing comfortable footwear and using appropriate stretching can help control symptoms. Taping or orthoses may offer additional support when indicated, while activity is rebuilt gradually. The objective is neither complete avoidance of loading nor exercising through every warning sign, but matching demands to current capacity.

Progress is best judged through several measures rather than pain alone. Walking tolerance, confidence on stairs, heel-raise performance and the ability to resume valued activities can all reveal useful changes. If improvement stalls despite appropriate participation, reviewing the diagnosis, exercise dose and total daily workload is preferable to assuming that more repetitions or a different gadget will necessarily solve the problem.

The Fasciitis Fighter is a potentially useful aid for progressive rehabilitation of plantar heel pain. Its rationale is credible, but evidence for strengthening should not be confused with proof of brand-specific superiority. Correct diagnosis, individualised progression and sustained adherence remain more important than the equipment itself.

Erythromelalgia is an uncommon condition characterised by episodes of burning pain, increased skin temperature, and redness, most frequently affecting the feet. Although its name is unfamiliar to many people, its effects can be profound: walking, wearing shoes, sleeping, and working may become difficult. Symptoms range from occasional discomfort to persistent, disabling pain. The condition involves abnormal interactions between peripheral nerves and the small blood vessels supplying the skin. Recognising its characteristic presentation, investigating possible underlying disease, and developing an individualised management plan are essential, particularly because some seemingly helpful remedies can damage the feet.

Clinical features and triggers

The typical episode involves hot, painful, red feet, often affecting the toes and soles. Both feet are commonly involved, although symptoms can be asymmetrical or confined to one foot. Redness may be less obvious in darker skin, making warmth, swelling, and the symptom history particularly important. Some people initially experience itching or tingling that progresses to intense burning. Episodes can last minutes, hours, or occasionally days; others experience relatively continuous symptoms.

Heat is the most characteristic trigger. Warm weather, hot baths, exercise, tight footwear, and heavy bedding may provoke attacks. Standing with the feet dependent can also worsen symptoms, while elevation and gentle cooling often provide relief. Alcohol, spicy foods, and emotional stress trigger symptoms in some individuals. Night-time flares are particularly disruptive because warmth beneath bedclothes can prevent sleep. Repeated pain and sleep disturbance can subsequently affect mood, concentration, mobility, and social participation.

Causes and mechanisms

Erythromelalgia is generally classified as primary or secondary. Primary disease may be inherited, occur sporadically, or have no identifiable cause. Some inherited cases involve variants in the SCN9A gene, which encodes the Nav1.7 sodium channel in pain-sensing nerves. These variants can make nerves excessively excitable, allowing normally tolerable warmth to generate severe pain. However, not everyone with primary erythromelalgia has an identifiable SCN9A variant.

Secondary erythromelalgia occurs in association with another disorder or, occasionally, medication exposure. Important associations include essential thrombocythaemia and polycythaemia vera, blood disorders involving excessive production of particular blood cells. Peripheral neuropathies and certain autoimmune conditions are other recognised associations. Mechanisms differ between patients: abnormal nerve signalling, disturbed regulation of skin blood flow, and platelet-mediated microvascular problems may contribute. Consequently, visibly red, warm feet do not necessarily indicate healthy tissue perfusion; increased superficial blood flow may coexist with inefficient oxygen delivery in some proposed disease models.

Diagnosis and differential diagnosis

Diagnosis is primarily clinical because no single test reliably confirms every case. A clinician assesses the relationship between burning pain, warmth, colour changes, triggers, and relief. Photographs taken during spontaneous attacks are useful when the feet appear normal at an appointment. A symptom diary can document timing, footwear, activity, and environmental temperature without deliberately provoking painful episodes.

Assessment should include vascular, neurological, and skin examination. A full blood count is important when investigating associated blood disorders, while further testing depends on the history and examination. Follow-up blood counts may be appropriate because erythromelalgia can precede recognition of a myeloproliferative disorder. Genetic testing is considered selectively, especially with early onset or a strong family history.

Other causes of painful red feet must be considered, including cellulitis, gout, contact dermatitis, peripheral neuropathy, and complex regional pain syndrome. A newly hot, swollen foot in someone with diabetes and neuropathy also requires urgent assessment for Charcot neuroarthropathy. Fever, spreading redness, wounds, or sudden unilateral swelling should not automatically be attributed to erythromelalgia.

Conservative management and foot protection

Management begins with education and practical trigger reduction. Lightweight, breathable footwear with adequate width can minimise heat retention and pressure. Socks should be selected according to comfort and moisture control rather than assumed therapeutic benefit. Pacing activity, taking breaks from prolonged standing, and keeping the sleeping environment comfortably cool may reduce attacks. Complete inactivity should be avoided where possible, because deconditioning can create additional disability.

Cooling requires particular caution. A fan or a briefly applied cool, wrapped gel pack may help, but ice, freezing packs, and cold-water immersion should be avoided. Repeated soaking can cause maceration, ulceration, infection, and cold injury. Relief can encourage increasingly prolonged cooling, creating a damaging cycle. People with reduced sensation or poor circulation are especially vulnerable. Gentle cooling, skin inspection, and elevation are safer principles than attempting to make the feet extremely cold.

Podiatric care can address footwear difficulties, pressure lesions, skin damage, and safe activity. Orthoses do not treat the underlying disorder, although selected modifications may improve comfort when mechanical problems coexist. Any device must avoid excessive bulk, pressure, or heat retention.

Regular review is valuable because tolerance of footwear and activity can change over time. Patients should report new blisters, cracks, or ulcers promptly rather than intensifying cooling. Coordinated care between primary care, dermatology, neurology, haematology, and podiatry may be needed, depending on the suspected cause and complications. Treatment plans should account for work demands, sleep disruption, and access to suitable footwear.

Medical treatment and prognosis

Treating an identifiable underlying disorder is central to secondary erythromelalgia. Aspirin can be particularly effective in platelet-mediated erythromelalgia associated with myeloproliferative disease, but it is not a universal treatment and should not be started without medical assessment. Bleeding risk, interactions, and contraindications must be considered.

Other treatments aim to reduce pain or modify nerve activity. Options include topical lidocaine, compounded preparations, gabapentin or pregabalin, and selected antidepressants used for neuropathic pain. Sodium-channel blockers, such as mexiletine or carbamazepine, may help selected patients, including some with inherited disease. These medicines require appropriate supervision and sometimes specialist monitoring. Responses vary substantially, and evidence for many treatments comes from small studies or case reports rather than large trials. Refractory cases may require specialist pain services; invasive treatments are reserved for carefully selected circumstances.

Prognosis is variable. Some people achieve reasonable control through trigger management and medication, whereas others experience persistent symptoms and considerable functional limitation. Psychological support and pain rehabilitation can improve coping without implying that the symptoms are imaginary. Ultimately, effective care combines accurate diagnosis, investigation of treatable causes, protection of vulnerable skin, and realistic, collaborative treatment goals. For erythromelalgia affecting the feet, preserving comfortable movement and preventing treatment-related injury are as important as reducing the burning pain itself.

Erosio interdigitalis blastomycetica is a superficial yeast infection affecting the skin between adjacent fingers or toes. Although classically described on the hands, it also occurs in the foot, where it represents a form of interdigital candidiasis. The condition is usually associated with Candida albicans, an opportunistic yeast that thrives in warm, moist environments. Despite its historical name, it is not caused by Blastomyces, the fungus responsible for blastomycosis. Recognising this distinction helps prevent confusion about its cause, significance, and treatment.

The interdigital spaces provide favourable conditions for infection when moisture accumulates. Closely apposed toes, enclosed footwear, excessive sweating, and inadequately dried feet create a humid environment. Prolonged moisture softens the outer skin layer, producing maceration and weakening its protective barrier. Friction between neighbouring toes further damages this vulnerable surface, allowing Candida to proliferate. Consequently, the disorder reflects an interaction between microbial growth and local environmental conditions rather than simply exposure to a fungus. Persistent dampness also explains why medication alone may not prevent recurrence.

Several factors increase susceptibility. People wearing occlusive work boots or persistently damp footwear may be particularly vulnerable. Diabetes, especially when blood glucose is poorly controlled, increases the risk of candidal skin infections. Immunosuppression, including that associated with systemic corticosteroids or chemotherapy, can also facilitate infection. Broad-spectrum antibiotics may contribute by disturbing the normal microbial balance. However, interdigital candidiasis can develop without an underlying systemic illness, and its presence should not automatically be interpreted as evidence of diabetes or immune deficiency.

The characteristic lesion is a moist, red, superficial erosion bordered by whitish, softened skin. The affected web space may appear raw or glazed, with peeling at its margins. Itching, burning, tenderness, and painful fissuring can occur, particularly when walking creates friction. Small peripheral papules or pustules may support a candidal diagnosis, although these are not always evident in narrow toe spaces. Appearance alone is insufficient for certainty because several infectious and inflammatory disorders produce similar interdigital changes. Mixed infections can further obscure the clinical picture.

The main diagnostic challenge is distinguishing candidiasis from interdigital tinea pedis, commonly called athlete’s foot. Tinea is caused by dermatophytes rather than Candida, but both can cause scaling, maceration, and fissuring. Other possibilities include irritant or allergic contact dermatitis, erythrasma, and bacterial toe-web infection. Marked malodour, discharge, or greenish discoloration should raise suspicion of bacterial involvement, including Pseudomonas. Psoriasis occasionally enters the differential diagnosis. Therefore, an apparent fungal infection that does not improve with appropriate treatment warrants reassessment rather than repeated empirical prescriptions.

Diagnosis combines clinical examination with laboratory testing when the presentation is uncertain, recurrent, or treatment-resistant. Microscopy of skin scrapings prepared with potassium hydroxide may demonstrate budding yeast and pseudohyphae. Fungal culture can help identify the organism, while bacterial sampling is useful when secondary infection is suspected. Importantly, recovering Candida does not necessarily establish that it is the primary cause: yeasts can colonise already damaged skin. Laboratory findings must therefore be interpreted alongside the lesion’s appearance, symptoms, and response to treatment. Biopsy is rarely necessary.

Management begins with correcting the local environment. Feet should be washed gently and dried carefully, particularly between the toes. Changing damp socks, choosing breathable footwear, and allowing shoes to dry between uses reduce retained moisture. Excessive sweating may require additional management. Heavy moisturisers should generally not be applied within already macerated web spaces because they can increase occlusion. Harsh antiseptics, aggressive rubbing, and attempts to peel away softened skin may worsen barrier damage. Practical advice should account for occupational footwear requirements and the person’s ability to perform foot care.

Topical antifungal treatment is usually sufficient for localised disease. An azole such as clotrimazole or miconazole is commonly used; nystatin is another option for confirmed candidiasis. Unlike azoles, nystatin does not treat dermatophyte infections, making diagnostic accuracy important. Treatment duration depends on the preparation and clinical response. Oral antifungals, such as fluconazole, may be considered for extensive or refractory disease under medical supervision. Drug interactions and contraindications require review. Potent corticosteroids or steroid-only treatment should be avoided because they can mask infection and encourage persistence.

Although usually superficial, interdigital erosions can provide an entry point for bacteria and contribute to cellulitis. Spreading redness, warmth, swelling, increasing pain, fever, or an open wound requires prompt clinical assessment, especially in people with diabetes, neuropathy, or poor circulation. Prognosis is generally good when both yeast overgrowth and moisture are addressed. However, evidence specifically concerning toe-web disease is limited, and much management draws on broader candidal intertrigo guidance. Ultimately, successful care depends on accurate diagnosis, appropriate antifungal therapy, and sustained protection of the interdigital skin barrier.

Prevention also involves recognising early recurrence. Regular inspection can identify renewed whitening, soreness, or cracking before erosions enlarge. People unable to see or reach their feet may benefit from assistance or podiatry review. Persistent episodes should prompt investigation of continuing moisture and contributing factors.

References

1. Schlager E, et al. Erosio interdigitalis blastomycetica: A review of interdigital candidiasis. Dermatology Online Journal. 2018. PubMed.
2. DermNet. Candidal intertrigo. Clinical guidance.

Foot calluses are areas of thickened skin that develop in response to repeated pressure and friction. They commonly occur beneath the forefoot, around the heels, and along the edges of the toes. Although callus initially protects the skin, excessive accumulation can become uncomfortable, crack, or contribute to footwear problems. Electric callus removers offer a convenient way to reduce this thickening at home. However, their usefulness depends on appropriate selection, careful technique, and recognition that removing callus does not eliminate its underlying cause.

How electric callus removers work

Most electric callus removers use a rotating abrasive roller or disc to wear away the outer layers of hardened skin. Different attachments provide varying degrees of abrasion, while some devices offer adjustable speeds or pressure sensors. Unlike blades, which cut through tissue, these tools gradually abrade its surface. Nevertheless, they can still damage healthy skin if pressed firmly or held against one area for too long. Their powered action reduces manual effort, but does not automatically make them safer than an ordinary foot file.

Callus consists predominantly of accumulated cells in the stratum corneum, the outermost layer of the epidermis. Carefully reducing excessive thickness may improve comfort and make rough heels feel smoother. Electric devices can be helpful for people who find manual filing tiring, provided they can comfortably reach and inspect their feet. However, substantial comparative clinical evidence establishing that consumer electric removers provide better long-term outcomes than manual files or other conservative treatments is limited. Convenience should not be confused with proven therapeutic superiority.

Benefits and limitations

The main advantages are accessibility, ease of use, and the ability to maintain smoother skin between professional appointments. Regular, gentle treatment may prevent minor accumulations from becoming excessively thick. Devices with replaceable heads also allow worn abrasive surfaces to be renewed. However, callus commonly returns because the mechanical forces producing it remain. Tight shoes, prominent bones, altered walking patterns, and repeated loading can all contribute. Without addressing these factors, powered filing becomes maintenance rather than a lasting solution.

It is also important to distinguish calluses from other lesions. A corn is usually more localised and may contain a central keratin core, while plantar warts can resemble thickened skin. Painful, unusual, bleeding, or rapidly changing lesions should be assessed rather than repeatedly filed. Electric removal cannot diagnose these conditions and may cause trauma or delay appropriate treatment. Extensive heel fissures likewise require more than cosmetic smoothing, particularly when cracks extend into living skin or show signs of infection.

Safe use

For a healthy person with normal sensation and circulation, conservative use begins with checking the skin and following the manufacturer’s instructions. Some devices are designed for dry skin, whereas others permit wet use; these instructions are not interchangeable. Use light pressure, keep the head moving, and make brief passes rather than attempting complete removal in one session. The goal is to reduce excessive thickness while preserving a protective layer. Stop immediately if tenderness, burning, marked redness, or bleeding occurs.

Avoid using the device over broken, inflamed, infected, or recently injured skin. Do not combine aggressive filing with strong chemical corn removers unless a clinician has advised this approach. Clean the device and attachments as directed, allow them to dry, and avoid sharing abrasive heads. Afterwards, apply a suitable moisturiser to intact skin. Urea-containing creams can help soften thickened skin, although higher concentrations may irritate and should be selected carefully. Moisturiser should generally not be applied between toes, where excess moisture encourages maceration.

A useful routine is to inspect the feet regularly and treat small amounts of hard skin only when necessary. Increasing speed, pressure, or treatment frequency to achieve perfectly soft soles can remove too much protective tissue and create unnecessary soreness instead of improving foot health.

When professional advice is needed

People with diabetes, peripheral neuropathy, poor circulation, previous foot ulceration, or other high-risk foot conditions should not independently use electric callus removers without professional advice. Reduced sensation can conceal injury, while impaired circulation can delay healing. Even a small abrasion may develop into a serious wound. In diabetes, callus can also indicate excessive pressure and conceal underlying tissue damage. A podiatrist can assess risk, reduce callus appropriately, and recommend pressure redistribution, suitable footwear, or orthoses when indicated.

Persistent pain, recurrent heavy callus, deep cracks, discharge, spreading redness, or an open wound warrants clinical assessment. Sudden warmth, swelling, or skin breakdown in a high-risk foot requires prompt attention rather than further home treatment. Professional care is particularly valuable when limited vision, reduced flexibility, or difficulty reaching the feet makes accurate filing unsafe. These practical limitations matter as much as the device’s advertised safety features.

Ultimately, electric callus removers are maintenance tools, not cures. Used gently on suitable feet, they can improve comfort and appearance. Their safest role is alongside moisturising, properly fitting footwear, and management of abnormal pressure, with professional assessment whenever symptoms or medical risks make self-treatment inappropriate.

Enko running shoes promised a dramatic departure from conventional footwear. Instead of relying mainly on foam cushioning, they incorporated a conspicuous mechanical suspension system beneath the foot. Their springs and articulated soles attracted attention from runners, designers and technology enthusiasts. However, the anticipated footwear revolution never materialised. The clearest answer to what happened is financial: the French company entered judicial liquidation in September 2019. Its story illustrates the difference between developing an intriguing invention and establishing a sustainable running-shoe business.

An ambitious mechanical alternative

Enko was developed by French engineer and runner Christian Freschi, who reportedly spent approximately twelve years refining the concept before its emergence in international coverage in 2015. An Indiegogo campaign helped introduce the shoes to potential customers. Their appeal was immediately understandable: if suspension protected cyclists from uneven surfaces, perhaps a comparable mechanism could make running more comfortable. Rather than resembling ordinary trainers, Enko shoes looked like compact machines attached to the feet.

The design used springs and a moving sole structure to compress under loading and rebound as the runner progressed through each step. Spring options were matched to the user’s body weight. The later G4 model offered seven cushioning categories covering runners weighing approximately 45–115 kilograms. A lever selected walking or running modes, while replaceable outsole studs were intended to extend service life. Enko promoted substantial shock absorption and durability, including a claimed lifespan of around 2,000 kilometres.

These features were genuinely distinctive, but the promotional language required caution. A spring can store and return mechanical energy; it cannot create energy. Furthermore, visible rebound does not establish that a shoe reduces the metabolic cost of running. Any benefit depends on the timing and direction of energy return, shoe weight, stability and the runner’s response. Similarly, reducing an impact measurement does not automatically demonstrate fewer injuries. Running injuries reflect interacting factors, including training load, tissue capacity and previous injury. Establishing clinical advantages would have required comparative studies following runners over time, rather than relying on demonstrations, testimonials or laboratory measurements of the suspension mechanism considered separately from its wearer.

Promise met practical compromises

Enko was more than a prototype that disappeared before reaching consumers. A July 2018 review in Canadian Running described running in the G4 and reported a noticeable spring-assisted sensation, a comfortable upper and a smooth transition towards the forefoot. The reviewer considered it potentially useful for longer, easier runs. These observations help explain why the shoes developed an interested audience: some runners genuinely enjoyed their unusual cushioning rather than merely admiring the engineering.

Nevertheless, the same review revealed significant compromises. The tested women’s size 8.5 weighed about 380 grams, substantial for performance running footwear. The reviewer also felt that the spring’s reloading limited rapid stride turnover and did not recommend the shoes for speed training. Walking initially felt awkward, and temporary calf tightness occurred during adaptation. Such observations are individual experiences, not controlled evidence, but they demonstrate that the suspension changed more than underfoot softness. It also changed the practical running experience.

Price presented another obstacle. The G4 retailed for approximately C$492 in that review, making it an expensive experiment for runners accustomed to conventional shoes. Promised durability could theoretically offset the purchase price, but buyers also needed confidence in replacement parts, warranties and continuing support. A shoe with specialised moving components creates different ownership expectations from a straightforward foam-soled trainer. These characteristics plausibly constrained its appeal, although the available records do not establish their individual contributions to the company’s failure.

The documented end of the business

The company’s disappearance is not simply an inference from an inactive website. French corporate records reproduced by Pappers identify ENKO, company number 799369855, as entering judicial liquidation on 11 September 2019. The court fixed its cessation-of-payments date at 9 August 2019, and the record states that activity ceased completely. On 1 March 2023, the liquidation was closed for insufficient assets. The company was removed from the commercial register on 2 March 2023. These dates distinguish the operational collapse from its later administrative conclusion.

What those records do not provide is a detailed commercial post-mortem. It would therefore be misleading to claim confidently that Enko failed because the shoes were ineffective, because runners rejected springs, or because a sporting authority banned the business. Financial insolvency is documented; the precise combination of sales, production costs, financing and operational difficulties is not established by the sources reviewed. Equally, enthusiastic product coverage should not be mistaken for independent proof of injury prevention or superior running economy.

Ultimately, Enko’s fate was the closure of an ambitious footwear venture, not a definitive scientific rejection of mechanical cushioning. Its shoes offered a striking alternative but combined novelty with weight, expense and unfamiliar mechanics. Their lasting lesson is that successful running footwear must deliver more than an impressive rebound: it needs convincing benefits, everyday usability, dependable support and a business capable of surviving beyond the initial excitement.

Sources

• Pappers: ENKO company record and liquidation notices.
• Canadian Running: “Shoe Review: ENKO G4,” 20 July 2018.
• Core77: “Enko’s Energy-Returning Running Shoes,” 21 January 2015.

A Durlacher corn is a small, often intensely painful lesion that develops beside the toenail, usually along the outer edge of the fifth, or little, toe. Also called a Lister’s corn, it occupies the narrow space between the nail and the surrounding skin. Its position distinguishes it from the more familiar corn over a toe joint or beneath the forefoot. Although easily overlooked, it can make ordinary footwear uncomfortable and walking unpleasant. Understanding this condition requires attention to local pressure, toe structure, and the possibility that an apparent corn is actually an accessory portion of toenail.

Development and causes

Conventionally, a Durlacher corn is described as a localised area of hyperkeratosis: thickening of the outer skin layer in response to repeated mechanical stress. Pressure and friction stimulate keratin accumulation, producing a compact lesion that presses into sensitive underlying tissues. The narrow nail groove leaves little room for this extra material, so even a tiny lesion may cause considerable pain. A corn does not have a true root, although its dense central keratin can resemble one. Removing that material can relieve discomfort, but does not necessarily eliminate the forces responsible for its formation.

Footwear is an important contributor. Narrow toe boxes squeeze the little toe against the shoe, while firm seams or stiff uppers can concentrate pressure beside the nail. Toe deformity may increase this loading. A fifth toe that rotates inward can expose its outer nail margin to pressure from both footwear and the ground. Prominent underlying bone, reduced soft tissue cushioning, and stiffness may also contribute. Fusion of the middle and distal toe bones, termed symphalangism, has been associated with these lesions in clinical reports, although its precise importance has not been established through strong comparative research.

Symptoms and diagnosis

Patients commonly describe a sharp, focal pain at the edge of the little toenail, particularly when wearing enclosed shoes. The lesion may look like a hard sliver, an additional nail fragment, or a small yellowish thickening. Some people therefore assume that they have an ingrown toenail or fungal infection. Diagnosis usually involves careful inspection and palpation, assessment of footwear, and examination of toe alignment. A podiatrist also considers alternative explanations, including an ingrown nail, wart, foreign body, or another nail disorder. Persistent ulceration, bleeding, unusual pigmentation, or unexplained enlargement warrants further investigation rather than repeated routine corn treatment.

Assessment should also include circulation and sensation, because these influence treatment safety. The clinician should ask when symptoms occur, whether both feet are affected, and whether previous removal produced lasting relief or only a relatively brief improvement.

An important diagnostic qualification is that not everything labelled a Durlacher corn is necessarily thickened skin. Published descriptions of accessory fifth toenails show that a small additional nail plate can lie beside the main nail and resemble a corn. Histological examination in reported cases has confirmed genuine nail tissue. These accessory nails may have an associated groove or split and can occur on both feet. Consequently, clinicians should distinguish pressure-induced hyperkeratosis from a developmental nail variation, while recognising that both may coexist. This distinction matters because recurrent nail tissue will not be permanently resolved by treating it as ordinary callus.

Treatment and prevention

Initial management generally aims to reduce pressure and relieve symptoms. Shoes should provide sufficient width and depth around the toes, with soft uppers and minimal irritating seams. Carefully selected padding or a silicone toe protector may help, provided it does not make the shoe tighter. Professional reduction of a true corn can provide substantial relief by removing compacted keratin. However, recurrence is common if footwear pressure or toe deformity remains unchanged. Regular review may therefore be appropriate. Moisturising dry surrounding skin can improve comfort, but cannot correct a bony prominence or remove an accessory nail-producing structure.

Self-treatment requires caution. Digging beside the nail with blades, scissors, or sharp instruments can damage skin and introduce infection. Acid-containing corn removers may burn adjacent healthy tissue, especially in the confined nail groove. People with diabetes, neuropathy, poor circulation, or a previous foot ulcer should seek professional assessment rather than attempting removal themselves. Redness, warmth, swelling, drainage, or an open wound requires prompt clinical attention. Persistent pain despite appropriate footwear and conservative care may justify imaging or specialist assessment, particularly when an underlying bony prominence, substantial toe deformity, or accessory nail is suspected.

Surgery is reserved for selected, persistently symptomatic cases and should address the actual diagnosis. Options may include correcting a focal bony prominence or toe deformity, or removing a painful accessory nail with appropriate treatment of its matrix. Potential complications include infection, delayed healing, nail distortion, and recurrence. Evidence specific to Durlacher corns consists largely of clinical descriptions and small reports, so outcomes should not be overstated. Ultimately, successful management depends on identifying whether the problem is corn, nail, or both, reducing mechanical irritation, and choosing treatment proportionate to symptoms and risk.

References

• Haneke, E. (2015). Double nail of the little toe. Skin Appendage Disorders, 1(4), 163–167.
• Fishco, W. D. (2011). Key considerations in treating Lister’s corn. Podiatry Today.
• Alder, D. C., Fishco, W. D., & Ruch, J. A. (1998). Surgical treatment of Lister’s corn: A case illustration. Journal of the American Podiatric Medical Association, 88(1), 30–33.

Limited joint mobility is an often overlooked musculoskeletal complication of diabetes mellitus. It involves progressive stiffness and reduced movement, particularly in the small joints of the hands and feet. When the hands are affected, the condition is commonly called diabetic cheiroarthropathy or diabetic stiff hand syndrome. Although usually less immediately threatening than cardiovascular disease or kidney failure, it can interfere with everyday activities, alter walking mechanics, and contribute to diabetic foot problems. Recognising this condition is therefore important for preserving function and identifying people who may need closer assessment for other diabetes complications.

Causes and underlying mechanisms

Limited joint mobility occurs in both type 1 and type 2 diabetes. Its reported prevalence varies considerably because studies use different definitions, examination methods, and patient populations. Longer diabetes duration and greater cumulative exposure to hyperglycaemia are important associations, although ageing and other musculoskeletal conditions also influence joint movement. The condition is not inevitable, and restricted movement in someone with diabetes should not automatically be attributed to it.

The principal proposed mechanism is the effect of chronic hyperglycaemia on connective tissue. Glucose attaches to proteins through non-enzymatic glycation, eventually producing advanced glycation end products. These accumulate in long-lived proteins such as collagen, which provides structural support in skin, tendons, ligaments, and joint capsules. Additional collagen cross-linking makes these tissues less elastic and more resistant to normal turnover. Consequently, structures surrounding the joints become thicker and stiffer, progressively restricting movement.

Other mechanisms may contribute, including altered collagen metabolism, oxidative stress, inflammation, and microvascular dysfunction. These processes can affect tissue quality and repair. However, the relative contribution of each remains uncertain, and limited joint mobility is better understood as a multifactorial connective-tissue disorder than simply the result of one biochemical pathway.

Clinical presentation and diagnosis

In the hands, limited joint mobility typically develops gradually and is often painless. The fingers become difficult to straighten fully, and fixed flexion contractures may develop. The overlying skin can appear thickened, tight, and waxy. Reduced grip strength and dexterity may make writing, fastening buttons, opening containers, or managing diabetes equipment more difficult. Nevertheless, some people have obvious examination findings without noticing substantial disability.

Two simple clinical manoeuvres help identify hand involvement. In the prayer sign, the person presses the palms and fingers together; incomplete contact between opposing fingers suggests restricted extension. In the tabletop sign, the person cannot place the palm and fingers completely flat on a table. These findings support assessment but are not uniquely diagnostic of diabetic cheiroarthropathy. Examination should include active and passive movement, skin changes, pain, and functional limitations.

Other disorders must be considered, including osteoarthritis, inflammatory arthritis, systemic sclerosis, Dupuytren contracture, and trigger finger. Several can coexist with diabetes-related stiffness. Imaging and blood tests are not routinely necessary for a typical presentation but may help when symptoms suggest another diagnosis. Painful swelling, marked asymmetry, or rapid deterioration warrants further investigation rather than assuming uncomplicated limited joint mobility.

Effects on the feet and walking

Lower-limb involvement has particular clinical importance. Restricted movement may affect the ankle, subtalar joint, and metatarsophalangeal joints, especially the big toe joint. Normal walking requires these structures to accommodate the ground, allow the body to advance over the supporting foot, and enable effective propulsion. When their movement is reduced, compensatory gait patterns can develop, changing the distribution of plantar loading.

For example, restricted ankle dorsiflexion may contribute to increased forefoot loading, while limited big toe joint movement can alter push-off. These changes do not produce identical pressure patterns in everyone, but they may concentrate repeated stress beneath vulnerable areas. Callus can develop, and tissue injury becomes more likely when mechanical overload combines with peripheral neuropathy, which reduces protective sensation. Peripheral arterial disease can further compromise healing.

Limited joint mobility is therefore one contributor to diabetic foot ulcer risk, not an independent explanation for every ulcer. Assessment should integrate joint movement with sensation, circulation, deformity, footwear, skin condition, and previous ulceration. A newly hot, swollen foot requires urgent assessment for conditions such as active Charcot neuroarthropathy or infection, rather than being labelled ordinary diabetic stiffness.

Association with other complications

Research has associated limited joint mobility with diabetic retinopathy, nephropathy, and neuropathy. These relationships may reflect shared exposure to longstanding hyperglycaemia and connective-tissue changes. However, association does not establish that joint stiffness causes these complications or reliably predicts them in an individual. Its detection should prompt clinicians to check that recommended diabetes screening is current, rather than treating it as proof of underlying vascular disease.

Management and prevention

There is no established treatment that reliably reverses advanced diabetic cheiroarthropathy. Management aims to maintain movement, minimise disability, and prevent secondary problems. Individualised glucose management is important for overall health and may help prevent or slow progression, but established collagen changes and contractures should not be expected to disappear rapidly when glucose levels improve.

Physiotherapy and occupational therapy can provide gentle stretching, range-of-motion exercises, functional training, and advice about adapting daily tasks. Exercises should be tailored to the affected joints and accompanying conditions. Evidence supporting specific programmes is limited, so benefits should be described realistically. Forceful stretching is inappropriate, particularly where neuropathy, fragile skin, active ulceration, or suspected Charcot disease makes injury difficult to detect.

For foot involvement, podiatric care includes footwear assessment, callus management, and pressure redistribution when indicated. Appropriately fitted shoes, insoles, or selected rocker soles may accommodate restricted movement, but prescriptions require individual assessment. Daily foot inspection and prompt attention to skin damage remain essential. Analgesics may help coexisting painful conditions but do not reverse the underlying stiffness.

Regular review should assess practical outcomes, not merely joint angles. Important questions include whether the person can dress independently, handle medication safely, walk comfortably, and inspect their feet. Where hand stiffness prevents self-care, assistance from family members or carers may be necessary. This functional approach helps translate clinical findings into meaningful everyday support.

Limited joint mobility demonstrates how diabetes affects connective tissues as well as nerves and blood vessels. Although often painless, it can impair hand function and contribute to hazardous loading of the feet. Early recognition, appropriate differential diagnosis, coordinated rehabilitation, and preventive foot care can reduce its practical consequences and support long-term independence.

References

• Limited joint mobility syndrome in diabetes mellitus: A minireview. World Journal of Diabetes. 2015;6(9):1108–1112. PubMed.
• Smith LL, Burnet SP, McNeil JD. Musculoskeletal manifestations of diabetes mellitus. British Journal of Sports Medicine. 2003;37:30–35. PubMed.
• Starkman HS, Gleason RE, Rand LI, Miller DE, Soeldner JS. Limited joint mobility (LJM) of the hand in patients with diabetes mellitus: relation to chronic complications. Annals of the Rheumatic Diseases. 1986;45:130–135. PubMed.

Duchenne muscular dystrophy (DMD) is a progressive, X-linked genetic disorder caused by mutations affecting dystrophin, a protein that stabilises muscle fibres during contraction. It predominantly affects boys, although females can occasionally develop significant manifestations. Without adequate dystrophin, repeated muscle damage leads to degeneration and replacement of muscle tissue by fat and fibrosis. The lower limbs are particularly important because their deterioration affects walking, standing, transfers and independence. Lower-limb problems include progressive weakness, altered gait, contractures, foot deformity, pain and fractures. Understanding how these problems interact is essential for preserving function and quality of life.

Progressive Muscle Weakness

Weakness usually becomes evident in early childhood and initially affects proximal muscles, particularly the pelvic girdle and thighs. Children may struggle to run, jump, climb stairs or rise from the floor. Weakness of the hip extensors and knee extensors makes lifting the body against gravity increasingly difficult. A characteristic finding is Gowers’ sign: the child uses the hands to push against the floor and then “climbs” up the legs to reach standing. This manoeuvre compensates for insufficient proximal muscle strength rather than indicating a primary joint disorder.

The calves often appear enlarged, a feature called pseudohypertrophy. This enlargement largely reflects fatty and connective-tissue replacement and should not be mistaken for increased strength. As weakness progresses, walking becomes slower, falls become more frequent and endurance declines. Eventually, independent ambulation is lost, although timing varies considerably with disease severity and treatment. Glucocorticoids and other specialist-directed therapies can modify progression, making rigid age-based predictions inappropriate. Functional assessment should therefore focus on the individual’s abilities and changing needs.

Gait Abnormalities and Compensation

Lower-limb weakness produces recognisable compensatory gait patterns. Weak hip abductors reduce pelvic stability, contributing to a waddling gait and lateral trunk movement. Weak hip extensors encourage increased lumbar lordosis and altered trunk positioning. These adaptations help maintain balance and reduce the muscular demands of standing and walking, but they also increase energy expenditure and fatigue.

Toe walking commonly develops. Initially, ankle plantarflexion may help position the ground-reaction force anterior to the knee, supporting knee extension when the quadriceps are weak. Consequently, an unusual gait pattern is not always simply a deformity requiring correction; it may be an important compensation. Later, shortening of the calf muscles and Achilles tendon can produce fixed equinus. Reduced foot clearance, difficulty negotiating uneven surfaces and declining balance further increase fall risk. Gait assessment should distinguish flexible compensation from established contracture before treatment decisions are made.

Contractures and Foot Deformities

Contractures are persistent restrictions in joint movement caused by shortening of muscles and surrounding soft tissues. In DMD, they result from muscle imbalance, fibrosis, reduced movement and prolonged positioning. Ankle plantarflexion contractures are particularly common, while hip and knee flexion contractures become increasingly important as mobility declines. Contractures often accelerate after loss of walking because the lower limbs spend more time in flexed positions.

The feet may develop equinovarus, combining a downward-pointing ankle with inward turning of the hindfoot. Progressive deformity can impair shoe fitting, standing, transfers and positioning on wheelchair footplates. Abnormal loading may cause focal pressure, callus and discomfort. After independent walking is lost, maintaining comfortable foot alignment remains valuable for supported standing, skin protection and everyday care. Sensation is generally preserved, unlike in peripheral neuropathy, but limited movement can prevent effective pressure relief. Footwear and orthoses require regular checks for fit and skin irritation.

Bone Fragility, Fractures and Pain

Bone health is another major concern. Reduced weight-bearing and muscle forces diminish the stimulus for bone development, while long-term glucocorticoid treatment can further compromise skeletal strength. Delayed puberty and nutritional difficulties may contribute. Consequently, relatively minor trauma can cause lower-limb fractures, particularly involving the femur. A fracture may have consequences beyond the immediate injury: immobilisation can accelerate weakness and contracture, and a child with marginal walking ability may not recover previous ambulation.

Management requires prompt assessment and a plan that minimises unnecessary immobilisation while respecting fracture stability. Bone surveillance, adequate calcium intake and correction of vitamin D deficiency form part of comprehensive care. Established fragility fractures warrant specialist osteoporosis assessment, with intravenous bisphosphonates considered where indicated. Pain may also arise from muscle fatigue, contractures, poor seating or pressure from footwear. New focal pain should not automatically be attributed to muscular dystrophy, particularly after a fall or transfer incident.

Rehabilitation and Clinical Management

Management aims to preserve function, prevent avoidable secondary complications and maintain comfort, rather than reverse the underlying muscle disorder. Regular physiotherapy assessment should monitor joint range, muscle function, gait, fatigue and transfers. Gentle stretching of vulnerable muscle groups, especially the plantarflexors, hamstrings and hip flexors, is commonly recommended. Night-time ankle–foot orthoses may help maintain ankle positioning, provided they are comfortable and appropriately fitted. Evidence supporting particular contracture interventions is limited, so treatment requires individual review rather than assuming guaranteed benefit.

Submaximal activity, such as supported swimming or appropriately adapted cycling, can encourage participation without excessive loading. High-resistance exercise and strenuous eccentric activity should be avoided because dystrophin-deficient muscle is vulnerable to damage. Rest periods, accessible environments and mobility aids help conserve energy. Rigid daytime ankle bracing can interfere with compensatory walking and should not be prescribed indiscriminately. Supported standing may assist positioning and participation, but requires assessment of contractures, tolerance and fracture risk.

Surgery is reserved for selected situations. Correcting ankle deformity may occasionally benefit a person with sufficient remaining strength or improve positioning after ambulation is lost. However, excessive Achilles tendon lengthening can remove useful compensation and worsen walking. Decisions require coordinated neuromuscular, rehabilitation and orthopaedic input, alongside careful cardiac, respiratory and anaesthetic assessment.

As wheelchair use increases, seating and lower-limb support should accommodate changing posture without forcing painful correction. Caregivers need training in safe transfers and repositioning to reduce injury and pressure damage. Physiotherapists, occupational therapists, orthotists and podiatrists can collaborate on practical solutions. The person’s priorities should guide intervention, balancing potential functional gains against discomfort, treatment burden and disruption to school or family life.

Lower-limb problems in Duchenne muscular dystrophy reflect interacting muscle weakness, compensatory biomechanics, soft-tissue shortening and skeletal fragility. Their effects extend beyond walking to comfort, transfers, participation and independence. Individualised multidisciplinary care can limit secondary complications and support meaningful function throughout changing disease stages.

References

• Apkon, S. D., et al. (2018). Orthopedic and surgical management of the patient with Duchenne muscular dystrophy. Pediatrics, 142(Supplement 2), S82–S89. https://doi.org/10.1542/peds.2018-0333J
• Balachandran, U., Mustapich, T., & Ranade, S. C. (2025). Orthopaedic management in Duchenne muscular dystrophy. Journal of the Pediatric Orthopaedic Society of North America, 10, 100154. https://pmc.ncbi.nlm.nih.gov/articles/PMC12088117/
• Birnkrant, D. J., et al. (2018). Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. The Lancet Neurology, 17(3), 251–267. https://doi.org/10.1016/S1474-4422(18)30024-3
• Birnkrant, D. J., et al. (2018). Diagnosis and management of Duchenne muscular dystrophy, part 2: Respiratory, cardiac, bone health, and orthopaedic management. The Lancet Neurology, 17(4), 347–361. https://doi.org/10.1016/S1474-4422(18)30025-5